Pulmatrix To Acquire Eos Senolytix In Merger

Pulmatrix agreed to acquire Eos Senolytix in a definitive merger and secured $19.0 million of concurrent private financings. The deal provides additional capital to support Pulmatrix's clinical-stage programs and likely improves its development runway, presenting a mild positive for PULM equity but limited broader market impact.

Analysis

Pulmatrix agreed to acquire Eos Senolytix in a definitive merger and secured $19.0 million of concurrent private financings. The deal provides additional capital to support Pulmatrix's clinical-stage programs and likely improves its development runway, presenting a mild positive for PULM equity but limited broader market impact.